Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Prospective 2-Arm Cohort Interventional Trial Utilizing Ultra-Hypofractionated SBRT With or Without Short Course Androgen Deprivation Therapy For Unfavorable Intermediate Risk Prostate Cancer

NCT06397703 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT06397703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06397703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Prospective 2-Arm Cohort Interventional Trial Utilizing Ultra-Hypofractionated SBRT With or Without Short Course Androgen Deprivation Therapy For Unfavorable Intermediate Risk Prostate Cancer
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Recruiting
Start date
April 16, 2024
Completion date
April 16, 2031
Enrollment
392 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer